ArticleAmerican journal of translational research2026
Effects of Ilizarov transverse tibial transport combined with truncated human epidermal growth factor gel on glucose metabolism, inflammation, and pain in patients with diabetic foot.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of Ilizarov transverse tibial bone transport combined with truncated human epidermal growth factor gel in the treatment of Wagner grade 2-3 diabetic foot ulcer, and its effects on glucose metabolism, inflammation, pain, and lower limb circulation.
methodsA retrospective analysis was conducted on 98 patients treated from Oct 2022 to Dec 2024. Patients were divided into a combined therapy group (CG, n=50) and a surgery-only group (MG, n=48). All patients received standard care and tibial bone transport, while patients in the CG additionally received truncated human epidermal growth factor gel treatment. Glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2h-PBG), inflammatory markers, coagulation markers, visual analog scale (VAS) pain score, ankle-brachial index (ABI), and limb skin temperature before and after treatment, as well as overall clinical efficacy, were compared between the two groups.
resultsPost-treatment HbA1c, FBG, 2h-PBG, inflammatory and coagulation markers were significantly lower in the CG than in the MG (all
conclusionsCombined therapy can improve glucose metabolism, alleviate inflammation and pain, and enhance lower limb perfusion, demonstrating superior clinical efficacy compared to tibial bone transport alone in patients with Wagner grade 2-3 diabetic foot ulcer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.